JAMA Network
About The Study: In contrast to the standard of care, only one in four U.S. adolescent residential addiction treatment facilities offered buprenorphine and one in eight offered buprenorphine for ongoing treatment for opioid use disorder. By comparison, nearly two-thirds of adult residential facilities offer buprenorphine.
Authors: Caroline King, Ph.D., M.P.H., of the Oregon Health & Science University School of Medicine in Portland, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.6266)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
